Merck & Co.
Merck & Co. reported 13 stocks worth $526M in its 13F filing for Q2 2026, filed Aug 7, 2026. Its largest holdings are PSNL (35.8%), MRNA (30.7%) and KYMR (16.8%). Compared with Q1 2026, the fund opened new positions in TRDA, STRO and EVAX and sold out of TRDA, STRO and CARM.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 7 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PSNL Personalis Inc | $188M | 35.8% | 14M | No change | 7 of 7 | |
| 2 |  MRNA Moderna Inc | $162M | 30.7% | 2.3M | No change | 7 of 7 | |
| 3 |  KYMR Kymera Therapeutics Inc | $88.5M | 16.8% | 772K | No change | 7 of 7 | |
| 4 |  AKTS Aktis Oncology Inc | $30.7M | 5.8% | 953K | No change | 2 of 7 | |
| 5 |  EIKN Eikon Therapeutics Inc | $21.7M | 4.1% | 1.7M | No change | 2 of 7 | |
| 6 |  TRDA Entrada Therapeutics Inc | $12.8M | 2.4% | 1.7M | New position | 1 of 7 | |
| 7 |  STRO Sutro Biopharma Inc | $9M | 1.7% | 272K | New position | 1 of 7 | |
| 8 |  ALEC Alector Inc | $7.1M | 1.4% | 3.5M | No change | 7 of 7 | |
| 9 |  EVAX Evaxion AS | $3.8M | 0.7% | 1.2M | New position | 1 of 7 | |
| 10 |  VRDN Viridian Therapeutics Inc | $1.7M | 0.3% | 93K | No change | 7 of 7 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Reported value
last 7 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 7, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Merck & Co. 13F FAQ
What does Merck & Co. own?
Merck & Co. reported 13 stocks worth $526M in its 13F filing for Q2 2026, filed Aug 7, 2026. The table above lists every position in the filing (the top 10 without an account).
What did Merck & Co. buy and sell in Q2 2026?
Compared with Q1 2026: 3 new positions, 0 added to, 0 trimmed and 4 sold out. New positions include TRDA, STRO and EVAX. It sold all of TRDA, STRO and CARM.
When will Merck & Co. file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Merck & Co.'s portfolio worth?
The Q2 2026 filing reports $526M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.